Last updated: September 3, 2026
Amlodipine besylate and celecoxib are mature, largely genericized medicines with sharply different commercial profiles. Amlodipine is a high-volume, low-price antihypertensive sold by numerous manufacturers. Celecoxib retains higher unit economics because of branded prescription demand, differentiated COX-2 positioning, and a more concentrated initial generic market, but its originator exclusivity has ended.
Amlodipine’s financial trajectory is volume-led and deflationary. Celecoxib’s trajectory is a slower decline from branded peak sales toward a mixed branded-generic market. Neither drug has a meaningful biosimilar risk because both are small-molecule products. The principal commercial risks are generic price erosion, payer substitution, manufacturing scale, regulatory compliance, and residual method-of-use or formulation claims.
How do amlodipine besylate and celecoxib compare commercially?
| Attribute |
Amlodipine besylate |
Celecoxib |
| Primary class |
Dihydropyridine calcium-channel blocker |
Selective COX-2 nonsteroidal anti-inflammatory drug |
| Main indications |
Hypertension; coronary artery disease-related angina |
Osteoarthritis, rheumatoid arthritis, acute pain, primary dysmenorrhea |
| Originator brand |
Norvasc |
Celebrex |
| Originator company |
Pfizer |
Pfizer |
| FDA approval |
1992 |
1998 |
| Market status |
Mature generic market |
Branded and generic market |
| Generic launch |
2007 |
2014 |
| Biosimilar risk |
None |
None |
| Pricing profile |
Low unit price, high volume |
Higher unit price, stronger branded price retention |
| Main commercial driver |
Chronic prescription volume |
Branded demand, payer coverage, generic substitution |
| Main competitive threat |
Commodity pricing |
Generic conversion and COX-2 safety scrutiny |
| Current lifecycle stage |
Late-stage mature generic |
Late-stage branded-generic transition |
Amlodipine has broader routine use and a larger prescription base. Celecoxib has greater revenue density per prescription but a narrower patient population and more complex safety considerations.
What is the market position of amlodipine besylate?
Amlodipine is one of the most established antihypertensive ingredients in the U.S. and global markets. It is widely used as monotherapy and in fixed-dose combinations with agents such as benazepril, valsartan, olmesartan, atorvastatin, and hydrochlorothiazide.
Its clinical advantages include once-daily administration, long duration of action, extensive physician familiarity, and availability in low-cost generic form. Its principal adverse-effect limitation is dose-related peripheral edema.
The U.S. market is highly fragmented. Manufacturers commonly include Viatris, Teva, Sandoz, Lupin, Zydus, Dr. Reddy’s, Torrent, Alembic, and multiple private-label suppliers. Exact supplier shares change frequently because pharmacy-benefit managers and wholesalers reallocate volume based on price, supply reliability, and manufacturing quality.
Amlodipine market structure
Amlodipine’s commercial economics are defined by:
- High prescription volume.
- Low average selling prices.
- Multiple approved suppliers.
- Limited brand loyalty.
- Routine substitution at the pharmacy counter.
- Strong use in combination products.
- Low barriers to therapeutic interchange within the calcium-channel blocker class.
The active ingredient is inexpensive to manufacture relative to complex small molecules. The commercial bottleneck is usually not drug discovery or formulation innovation. It is reliable, compliant, high-volume production and distribution.
When did amlodipine lose exclusivity?
Amlodipine’s principal U.S. exclusivity period ended after the Norvasc patent estate was exhausted. Generic amlodipine approvals began in 2007, marking the transition from originator protection to a competitive generic market.
The key originator patent was U.S. Patent No. 4,572,909, covering amlodipine and related compounds. The patent was assigned to Pfizer-related entities and expired in the 2000s after statutory adjustments and extensions. The FDA approved the first generic versions of amlodipine besylate tablets in 2007.
| Milestone |
Approximate date |
| Norvasc U.S. approval |
1992 |
| Core amlodipine compound patent period |
Ended in the 2000s |
| First U.S. generic approvals |
2007 |
| Current U.S. market |
Multi-source generic |
| Residual originator protection |
No meaningful core exclusivity |
Amlodipine’s current patent risk is low for the basic tablet product. Any remaining claims are more likely to concern specific combinations, formulations, manufacturing processes, or use in a particular patient population rather than the active ingredient itself.
What patents protect amlodipine besylate products?
The original patent estate centered on the amlodipine molecule and pharmaceutically acceptable salts. Amlodipine besylate is the besylate salt used in Norvasc and most generic tablets.
Important patent categories include:
- Composition-of-matter patents. These covered the dihydropyridine compound and related chemical structures.
- Salt and pharmaceutical composition claims. These addressed pharmaceutically acceptable salts, including the besylate form.
- Tablet and dosage-form claims. These may cover excipient selection, dissolution characteristics, or specific dosage presentations.
- Combination-product claims. These may apply to products combining amlodipine with an ACE inhibitor, angiotensin receptor blocker, statin, or diuretic.
- Method-of-use claims. These may cover treatment of hypertension, angina, or cardiovascular-risk populations.
The basic amlodipine tablet is commercially exposed to generic competition. Combination products can retain narrower, product-specific patent positions, although their commercial value depends on whether the claims survive litigation and whether the combination has meaningful clinical or payer differentiation.
What is the market position of celecoxib?
Celecoxib has a different commercial profile from amlodipine. It is the only widely established selective COX-2 inhibitor with a large continuing U.S. prescription market after the withdrawal of rofecoxib and valdecoxib. Its value comes from perceived gastrointestinal tolerability advantages compared with nonselective NSAIDs, physician familiarity, and continued use in osteoarthritis, rheumatoid arthritis, and acute pain.
Celecoxib remains exposed to cardiovascular and gastrointestinal risk management. Prescribing decisions are influenced by patient age, cardiovascular history, renal function, gastrointestinal risk, dose, duration, and availability of lower-cost NSAIDs.
Pfizer commercialized celecoxib as Celebrex. Following generic entry, the market divided into:
- Pfizer’s branded Celebrex business.
- Authorized or licensed generic supply.
- Independent generic capsules.
- Hospital and institutional procurement.
- Cash-pay and discount-pharmacy channels.
Unlike amlodipine, celecoxib has retained a more substantial branded segment because some prescribers and patients continue to associate the product with established efficacy, supply reliability, and a recognized label.
When did celecoxib lose exclusivity?
Celecoxib’s core U.S. patent protection expired in the 2010s. Generic celecoxib entered the U.S. market in 2014 after patent litigation and settlement arrangements involving Pfizer and generic manufacturers.
The principal composition patent was U.S. Patent No. 5,466,823. Additional patents and pediatric exclusivity affected the precise timing and scope of generic entry. The FDA approved generic celecoxib capsules from multiple manufacturers beginning in 2014.
| Milestone |
Approximate date |
| Celebrex U.S. approval |
1998 |
| Core composition patent |
Expired in the 2010s |
| First major generic approvals |
2014 |
| Pediatric exclusivity impact |
Extended certain protections into 2015 |
| Current U.S. market |
Branded-generic |
| Core ingredient protection |
Expired |
The 2014 launch materially changed the product’s price structure. The effect was less absolute than the post-patent collapse of some small-molecule brands because celecoxib maintained branded demand and its generic market developed through staged entry.
What patents protect celecoxib products?
Celecoxib patent coverage has historically included:
- Composition-of-matter claims.
- Pharmaceutical composition claims.
- Capsule formulations.
- Dosage strengths.
- Treatment methods for arthritis and pain.
- Reduced gastrointestinal toxicity or selective COX-2 inhibition claims.
- Pediatric or age-specific indications.
- Manufacturing and crystallization processes.
The core molecule is no longer protected in the U.S. by meaningful originator exclusivity. Residual patent value depends on the specific claim and product. A narrow formulation or method-of-use patent may create litigation leverage, but it is unlikely to restore the economic position of the original compound patent.
The most relevant current barriers are regulatory rather than patent-based. These include bioequivalence requirements, manufacturing-site approvals, controlled supply of high-quality active pharmaceutical ingredient, pharmacovigilance, and compliance with labeling requirements.
What is the Orange Book status of amlodipine and celecoxib?
The FDA Orange Book identifies approved drug products, therapeutic-equivalence ratings, patents submitted by applicants, and periods of regulatory exclusivity. The practical Orange Book position is different for the two medicines.
| Product |
Orange Book position |
Commercial implication |
| Amlodipine besylate tablets |
Multiple therapeutically equivalent generic products |
Broad substitution and strong price competition |
| Celecoxib capsules |
Multiple approved generic products, alongside Celebrex |
Generic substitution with residual brand demand |
| Core originator patent protection |
Expired |
No broad compound-level barrier |
| Current Paragraph IV exposure |
Primarily relevant to later formulations or uses |
Limited effect on standard products |
For standard amlodipine tablets and standard celecoxib capsules, Orange Book-listed compound patents do not provide a current basis for blocking ordinary generic competition. Later products may rely on different patents, but the value of those patents must be assessed at the product and claim level.
Which companies are challenging amlodipine and celecoxib patents?
Amlodipine generic competition emerged from numerous manufacturers after the Norvasc estate expired. Because the core patent is long expired, current competition is generally not organized around active Paragraph IV litigation involving the basic tablet.
Celecoxib had more significant Paragraph IV activity before generic entry. Generic companies, including Teva and others, challenged listed Celebrex patents. Pfizer pursued litigation and entered settlement or commercial arrangements that helped establish the timing of generic access. The precise business terms varied by agreement and were not fully public in every case.
The principal litigation period was concentrated before 2014 generic launches. Current disputes are more likely to involve:
- Product-specific formulations.
- Manufacturing processes.
- Labeling and method-of-use claims.
- ANDA patent certifications.
- Contract manufacturing and supply obligations.
- Antitrust or settlement-related claims.
What is the financial trajectory for amlodipine besylate?
Amlodipine’s branded financial peak occurred before generic entry. Pfizer’s Norvasc generated substantial multibillion-dollar-class historical revenue across global markets during its protected period, although company reporting did not always separate every salt, geography, or combination product.
After generic entry, financial value shifted from the originator to a large number of generic manufacturers. The market’s trajectory has four stages:
Protected growth
Before patent expiry, Norvasc benefited from chronic use, broad guideline adoption, and once-daily dosing. Revenue depended on branded price, prescription growth, and international expansion.
Initial generic erosion
Generic entry reduced Pfizer’s price and volume rapidly. Pharmacy substitution redirected prescriptions to lower-cost suppliers.
Mature generic commoditization
Over time, average selling prices fell as more manufacturers entered. Large manufacturers retained value through scale, procurement access, and dependable supply rather than premium pricing.
Stable volume, declining nominal value
Amlodipine prescriptions remain durable because hypertension is chronic and prevalent. Revenue growth is limited because the market is mature and price competition is intense. Future value is concentrated in manufacturing efficiency, supply continuity, combination products, and emerging-market distribution.
The principal financial risk is sudden price compression after a new supplier enters or an incumbent manufacturer wins a major wholesaler contract. The principal upside is stable high-volume demand rather than price expansion.
What is the financial trajectory for celecoxib?
Celecoxib had a longer period of meaningful branded revenue than amlodipine because generic entry occurred later. Pfizer’s Celebrex business generated several billions of dollars annually at its historical peak. Following generic entry, branded sales declined, but the erosion was moderated by continued branded demand and the structure of the generic launch.
The financial trajectory has five drivers:
- Generic penetration. Greater substitution lowers branded volume and net price.
- Dose mix. Use of 100-mg and 200-mg capsules affects revenue and utilization.
- Chronic versus acute use. Chronic arthritis treatment supports recurring volume, while acute pain is more episodic.
- Payer policy. Formulary preference determines whether patients receive branded Celebrex or generic celecoxib.
- Safety perception. Cardiovascular risk concerns can reduce use or push prescribers toward nonselective NSAIDs.
Celecoxib has stronger residual commercial value than amlodipine because its brand remains clinically recognized and its market has fewer direct substitutes that replicate the same COX-2 positioning. Its long-term trajectory is still declining in branded terms. Generic volume can grow while total market revenue falls.
How do generic launch scenarios differ?
Amlodipine generic launch scenario
Amlodipine already operates in a fully mature generic market. A new entrant would face:
- Low prices.
- Established suppliers.
- Limited differentiation.
- High pharmacy substitution.
- Contracting pressure from wholesalers and purchasing groups.
A successful entrant would need a cost advantage, a reliable manufacturing record, or access to a distribution channel underserved by incumbent suppliers.
Celecoxib generic launch scenario
Celecoxib generic entry historically created more opportunity because the branded market was larger and unit prices were higher. A new entrant would need:
- FDA-approved ANDA status.
- Demonstrated bioequivalence.
- Consistent capsule supply.
- Competitive pricing.
- Payer and wholesaler access.
- Management of any remaining formulation or use patents.
Generic entry can produce substantial volume, but the market can become unprofitable if several suppliers compete aggressively for the same contracts.
How strong are the patent estates for amlodipine and celecoxib?
| Factor |
Amlodipine |
Celecoxib |
| Core composition patent |
Expired |
Expired |
| Standard tablet/capsule barrier |
Weak |
Weak |
| Formulation patent potential |
Low to moderate |
Moderate |
| Method-of-use patent potential |
Limited |
Moderate but narrow |
| Litigation leverage |
Low for standard product |
Historically meaningful, now reduced |
| Biosimilar protection |
Not applicable |
Not applicable |
| Manufacturing barrier |
Moderate |
Moderate |
| Overall originator estate |
Weak for basic product |
Weak for basic product, stronger historically |
Celecoxib had a more valuable historical estate because of its branded revenue base and later patent expiry. Amlodipine has greater current volume but weaker pricing power and lower patent-driven value.
What FDA regulatory issues affect both products?
Both medicines are approved small molecules regulated through abbreviated new drug applications for generic versions. The FDA evaluates generic products primarily through pharmaceutical equivalence and bioequivalence, supported by manufacturing and quality data.
Key regulatory issues include:
- Active pharmaceutical ingredient quality.
- Impurity control.
- Dissolution and stability.
- Manufacturing-site compliance.
- Labeling consistency.
- Adverse-event reporting.
- Supply-chain resilience.
- Recalls caused by contamination or specification failures.
Celecoxib carries greater label and pharmacovigilance sensitivity because NSAID use is associated with cardiovascular, gastrointestinal, renal, and hypersensitivity risks. Amlodipine has a more established chronic-use safety profile, although hypotension, edema, and drug interactions remain relevant.
What geographic markets offer the strongest commercial opportunity?
Amlodipine has broad geographic reach because hypertension treatment is chronic, guideline-supported, and compatible with low-cost generic supply. Growth opportunities are more likely in emerging markets, where diagnosis and treatment rates remain below those in the United States and Western Europe. Pricing remains constrained.
Celecoxib has stronger commercial potential in markets where:
- Branded prescribing remains common.
- COX-2 selectivity has clear clinical demand.
- Patients have access to prescription reimbursement.
- Arthritis prevalence is high.
- Generic substitution is less aggressive.
The U.S. remains commercially important for celecoxib, but payer controls and generic competition limit future branded expansion. International markets may support volume growth but generally at lower prices.
What licensing deals and settlements affect the products?
The most commercially important agreements were associated with celecoxib’s pre-generic litigation. Pfizer entered agreements with generic companies that addressed patent challenges and the timing or terms of market entry. These arrangements influenced the transition from Celebrex exclusivity to generic availability.
Amlodipine’s current market is more dependent on generic supply contracts, licensing of combination products, and manufacturing arrangements than on active originator patent settlements. Relevant agreements may involve:
- Authorized generic supply.
- Regional commercialization rights.
- Fixed-dose combination licenses.
- Contract manufacturing.
- API sourcing.
- Private-label distribution.
Because many commercial contracts are confidential, public disclosures generally provide only partial visibility into margins and transfer prices.
What revenue exposure remains for Pfizer?
Pfizer’s historical exposure to amlodipine and celecoxib was significant during their protected commercial periods. Current exposure is substantially different:
- Amlodipine is no longer a major originator growth asset.
- Celebrex retains branded revenue but faces continuing generic substitution.
- The economic importance of both products is small relative to Pfizer’s newer patented products.
- Celecoxib has greater residual brand value than amlodipine because Pfizer continues to own and market the Celebrex brand in relevant channels.
For investors, the key question is not whether either product will deliver material growth. The relevant issue is the rate of branded erosion, generic market stability, and the cost base required to maintain supply and regulatory compliance.
Key Takeaways
- Amlodipine besylate is a high-volume, low-price generic commodity with durable demand and limited patent value.
- Celecoxib is a mature branded-generic product with greater residual pricing power and a more valuable historical patent estate.
- Amlodipine generic entry began in 2007; celecoxib generic entry began in 2014.
- Both core composition patent estates have expired.
- Neither product faces biosimilar competition.
- Amlodipine revenue is driven by prescription volume and manufacturing efficiency.
- Celecoxib revenue is driven by branded retention, generic penetration, payer policy, and safety perception.
- Standard tablet and capsule products face low current patent barriers.
- Remaining commercial barriers are mainly manufacturing, regulatory, quality, distribution, and product-specific formulation issues.
- Future growth is unlikely to come from price expansion. It is more likely to come from geographic volume, combination products, and efficient supply.
FAQs About Amlodipine Besylate and Celecoxib
Is amlodipine besylate still protected by a patent?
The core amlodipine compound and standard amlodipine besylate tablet are no longer protected by meaningful U.S. originator exclusivity. Generic products are widely available.
Is celecoxib a generic drug or a brand-name drug?
Both. Celebrex is the originator brand, while multiple FDA-approved manufacturers sell generic celecoxib capsules.
Can celecoxib generics be automatically substituted for Celebrex?
FDA therapeutic-equivalence ratings determine substitution at the pharmacy level. State substitution laws, payer policy, and the specific product presentation also affect dispensing.
Are there fixed-dose combination patents for amlodipine?
Yes. Combination products containing amlodipine and other cardiovascular agents may have product-specific patents or regulatory protections, even though standard amlodipine tablets are genericized.
Which drug has the stronger long-term commercial outlook?
Amlodipine has the stronger volume outlook because hypertension treatment is chronic and widespread. Celecoxib has the stronger per-prescription economics but greater sensitivity to safety concerns, payer controls, and branded-to-generic conversion.
References
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2007). FDA approves first generic Norvasc tablets. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2014). FDA approves first generic Celebrex. U.S. Department of Health and Human Services.
-
Pfizer Inc. (Various years). Annual reports and Form 10-K filings. Pfizer Inc.
-
U.S. Patent and Trademark Office. (1986). U.S. Patent No. 4,572,909: Dihydropyridine derivatives. U.S. Department of Commerce.
-
U.S. Patent and Trademark Office. (1995). U.S. Patent No. 5,466,823: Substituted pyrazolyl benzenes useful as anti-inflammatory agents. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2015). Celecoxib prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2023). Amlodipine besylate prescribing information. U.S. Department of Health and Human Services.
